Apogee Therapeutics recently reported a higher full-year 2025 net loss of US$255.84 million and a wider basic loss per share, while also filing a US$287.29 million common stock shelf registration and ...
Albemarle has closed the sale of a controlling stake in Ketjen’s refining catalyst solutions business. The company is folding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results